新闻

DELRAY BEACH, Fla., May 18, 2026 /PRNewswire/ -- According to MarketsandMarkets, the Multiplex Assays Market is projected to grow from about USD 7.15 billion in 2026 to USD 10.65 billion by 2031, at a CAGR of 8.3%. Browse 312 market data Tables and 50 Figures spread through 350 Pages and in-depth TOC on "Multiplex Assays Market - Global Forecast to 2031" Multiplex Assays Market Size & Forecast: Market Size Available for Years: 2025-20312026 Market Size: USD 7.15 billion2031 Projected Market Size: USD 10.65 billionCAGR (2026-2031): 8.3% Multiplex Assays Market Trends & Insights: By product & service, consumables accounted for the largest share of 67.9% in 2025, primarily because they are included in every testing cycle rather than being linked to one-time capital purchases.By type, protein multiplex assays are expected to register the highest CAGR of 8.6% during the forecast period.By application, the research & development segment accounted for the largest market share of 61.6% in 2025. Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=61593314 Market drivers include rising demand for high-throughput diagnostic tools and the ability to analyze multiple biomarkers in a single sample. Other factors driving the market include increased incidence of infection, cancer, and autoimmune diseases. The increased adoption of precision medicine and the use of companion diagnostics are adding to the growing demand. Improvements in PCR technology, immunoassays, and sequencing techniques are driving market growth worldwide. Furthermore, market growth can be attributed to technological progress, which yields positive results in diagnostics and life sciences research. Highly sensitive multiplex platforms, advances in assay chemistry, and the adoption of laboratory automation have increased the efficiency of the test process and workflow productivity. Advanced software technologies, cloud connectivity, and analytics of collected data have also contributed to a better understanding of outcomes and decision-making processes. The increasing demand for accurate and efficient testing tools, driven by advances in technologies such as multiplex PCR, bead-based immunoassays, next-generation sequencing, and sample-to-answer platforms, is evident among healthcare providers, pharmaceutical firms, and research labs. Multiplex tests are becoming popular for disease profiling, companion diagnostics, and biomarker measurement to enable precise analysis across patient groups. By technology, the flow cytometry segment accounted for the largest market share in 2025. This market is classified into flow cytometry, fluorescence detection, multiplex real-time PCR, luminescence, next-generation sequencing (NGS), and other techniques. Some of the growth drivers of the flow cytometry segment are its superior sensitivity, multiparametric analysis capability, and high utility in immunology, oncology, and cellular research. In addition, the increasing prevalence of molecular diagnostics, the growing number of diagnostic centers, and technological advancements in automation and analysis are also anticipated to drive demand for multiplex assays. Request Sample Pages@https://www.marketsandmarkets.com/requestsampleNew.asp?id=61593314 By application, the clinical diagnostics segment accounted for the largest market share in 2025. The market is divided into the research & development and clinical diagnostics segments. Some of the key factors driving the growth of the clinical diagnostics segment are the rising demand for fast, accurate multi-target disease identification, the increasing incidence of infectious diseases and cancers, and the growing use of syndromic testing panels in healthcare facilities. Furthermore, the growing importance of early diagnosis, personalized therapy selection, and advancements in diagnostic infrastructure are driving this segment's growth. On the other hand, R&D demand remains robust owing to the rising discovery of biomarkers and drug development worldwide. By end user, the pharmaceutical & biotech companies segment accounted for the largest market share in 2025. This market is segmented into pharmaceutical & biotech companies, hospitals & diagnostic laboratories, academic & research institutes, contract research organizations, and other end users. Factors expected to drive growth in the pharmaceutical & biotech companies market include rising test volumes, the need for multiplexed analysis, and the growing adoption of automation in diagnostic procedures. In addition, an increase in the incidence of infections and cancers, along with improvements in healthcare infrastructure, is another driver of demand. North America dominated the multiplex assay market in 2025. The multiplex assay market is segmented into five geographical regions: Asia Pacific, Latin America, North America, Europe, and the Middle East & Africa. In 2026, North America held the largest market share in the multiplex assay market. This growth can be attributed to a highly advanced healthcare industry, the presence of well-established biotechnology and diagnostics companies, and the use of innovative technologies. Additionally, North America benefits from a significant number of advanced hospitals, research institutes, and diagnostic centers. An increase in the prevalence of infections and cancer cases is also driving market growth in this region. Inquire Before Buying@https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=61593314 Top Companies in Multiplex Assays Market: The Top Companies in Multiplex Assays Market include Thermo Fisher Scientific, Inc. (US), Illumina, Inc (US), Bio-Rad Laboratories, Inc. (US), Merck KGaA (Germany), DiaSorin S.p.A. (Italy), Revvity, Inc. (US), and bioMérieux (France), among others. Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting Related Reports: Lateral Flow Assays Market - Global Forecast to 2030 Molecular Diagnostics Market - Global Forecast to 2030 Immunoassay Market - Global Forecast to 2030 Cell Based Assays Market - Global Forecast to 2030 Flow Cytometry Market - Global Forecast to 2033 About MarketsandMarkets MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts. MarketsandMarkets SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency. To find out more, visit www.MarketsandMarkets.com or follow us on Twitter , LinkedIn and Facebook . Contact: Mr. Rohan Salgarkar MarketsandMarkets INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/5909825/MarketsandMarkets_Logo.jpg View original content:https://www.prnewswire.co.uk/news-releases/multiplex-assays-market-worth-10-65-billion-by-2031--marketsandmarkets-302774511.html © 2026 PR Newswire

The radiopharmaceuticals market is largely propelled by the rising incidence of chronic illnesses, including cancer, cardiovascular diseases, and neurological disorders, which is increasing the need for advanced diagnostic and treatment options. In addition, continuous innovations in imaging technologies, radiotracer design, and theranostic approaches have enhanced diagnostic precision, safety, and overall patient outcomes. Furthermore, improvements in healthcare infrastructure, growing awareness regarding early disease diagnosis, and supportive government policies are encouraging the wider adoption of nuclear medicine procedures. LAS VEGAS, May 18, 2026 /PRNewswire/ -- DelveInsight's Radiopharmaceuticals Market Insights report provides the current and forecast market analysis, individual leading radiopharmaceuticals companies' market shares, challenges, radiopharmaceuticals market drivers, barriers, trends, and key radiopharmaceuticals companies in the market. Radiopharmaceuticals Market Summary 2025 Radiopharmaceuticals Market Size: USD 10.7 Billion2034 Projected Radiopharmaceuticals Market Size: USD 24.1 BillionRadiopharmaceuticals Market Growth Rate (2026-2034): ~10% Largest Radiopharmaceuticals Market: North AmericaLargest Product Type (Diagnostic Products Segment): Iodine-125 Category under SPECTKey Companies in the Radiopharmaceuticals Market: Lantheus, Cardinal Health, GE Healthcare, Curium Pharma, Pharmalogic Holdings Corp., Novartis, Cambridge Isotope Laboratories, Inc., Sotera Health LLC, Bracco Imaging SpA, Jubilant Pharma Limited, NECSA Ltd., IBA Radiopharma Solutions, Bayer AG, Norgine, NorthStar Medical Radioisotopes, LLC, Eckert & Ziegler, Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Mallinckrodt PLC, ROTOP Pharmaka GmbH, and others To read more about the latest highlights related to the radiopharmaceuticals market, get a snapshot of the key highlights @ https://www.delveinsight.com/sample-request/nuclear-medicine-radiopharmaceuticals-market Key Factors Contributing to the Rise in Growth of the Radiopharmaceuticals Market Rising Prevalence of Chronic Diseases: The increasing global burden of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions is a major driver of radiopharmaceutical demand.Technological Advancements in Nuclear Medicine: Continuous innovations in nuclear imaging technologies, including PET and SPECT imaging systems, have improved diagnostic accuracy and treatment planning.Growing Demand for Precision and Personalized Medicine: Radiopharmaceuticals play a critical role in precision medicine by enabling targeted imaging and therapy tailored to individual patient characteristics.Increasing Investment in Research and Development: Government organizations, academic institutions, and pharmaceutical companies are investing heavily in nuclear medicine research and radiopharmaceutical development.Expansion of Healthcare Infrastructure and Imaging Facilities: The rising number of nuclear medicine centers, hospitals, and diagnostic imaging facilities worldwide is boosting the utilization of radiopharmaceuticals.Aging Global Population: The growing geriatric population is more susceptible to chronic diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions.Favorable Regulatory and Policy Support: Regulatory agencies are introducing supportive frameworks and faster approval pathways for innovative radiopharmaceuticals, encouraging pharmaceutical companies to develop and commercialize new products. Regional Radiopharmaceuticals Market Insights North America North America held the largest share of the radiopharmaceuticals market in 2025, accounting for approximately 42% of the global market. This leading position is attributed to the increasing incidence of cancer, cardiovascular disorders, and other chronic illnesses associated with lifestyle shifts and the widespread consumption of processed foods. Moreover, the strong presence of key regional companies, along with a rapidly expanding aging population that is more vulnerable to chronic diseases, is expected to further support market growth in the region. Europe The European radiopharmaceuticals market is expanding due to the increasing incidence of cancer, cardiovascular conditions, and neurodegenerative diseases. This growth is further supported by the growing need for early and precise diagnosis, along with the wider adoption of advanced imaging modalities such as PET and SPECT that enable accurate, non-invasive detection and monitoring of diseases. Asia-Pacific The Asia-Pacific radiopharmaceuticals market is witnessing significant growth due to the rising prevalence of cancer, cardiovascular diseases, and neurodegenerative conditions. This expansion is further supported by increasing healthcare investments, improvements in diagnostic infrastructure, and the growing utilization of advanced imaging technologies and radiopharmaceutical-based therapies. Get a sneak peek at the radiopharmaceuticals market dynamics @ Radiopharmaceuticals Market Trends Recent Developmental Activities in the Radiopharmaceuticals Market In March 2026, Lantheus Holdings, Inc. announced that the FDA had granted tentative approval to its Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent version of LUTATHERA (lutetium Lu 177 dotatate).In February 2026, Aktis Oncology announced that the FDA had awarded Fast Track designation to AKY-1189 for treating adult patients with locally advanced or metastatic urothelial cancer (mUC) who have progressed after prior systemic therapies. Developed using Aktis' miniprotein radioconjugate platform, AKY-1189 is engineered to deliver actinium-225 (225Ac), a powerful alpha-emitting radioisotope, directly to tumors expressing Nectin-4. Notably, around 80-90% of urothelial cancer patients exhibit positive Nectin-4 expression.In January 2026, the International Society for Pharmaceutical Engineering (ISPE) announced the creation of the ISPE Radiopharmaceuticals Community of Practice (CoP). This initiative aims to address the rapid expansion and distinct challenges within the radiopharmaceuticals sector, which is becoming increasingly important in advancing precision medicine, particularly for diseases such as cancer.In January 2026, Zonsen PepLib Biotech Inc. announced a global licensing agreement with Novartis for an undisclosed peptide-based candidate in the radioligand therapy (RLT) space. As part of the deal, Novartis has secured exclusive worldwide rights and will oversee the asset's development and commercialization.In January 2026, Swiss Rockets AG and Alloy Therapeutics, Inc. entered into a Master Research Agreement (MRA) to initiate a multi-target partnership focused on the discovery and development of next-generation radioligand therapeutics (RLTs) for oncology. The collaboration will be carried out through Swiss Rockets' radiotherapeutics subsidiary, Torpedo Pharmaceuticals AG.In March 2025, Telix Pharmaceuticals Limited announced that the United States Food and Drug Administration (FDA) had approved its New Drug Application (NDA) for Gozellix (TLX007-CDx, a kit for the preparation of gallium-68 [68Ga] gozetotide injection), Telix's next-generation PSMA-PET imaging agent for prostate cancer. What are Radiopharmaceuticals? Radiopharmaceuticals are specialized medicinal formulations that contain radioactive isotopes and are used in both the diagnosis and treatment of diseases, particularly in oncology, cardiology, and neurology. These agents typically consist of a radioactive component (radioisotope) linked to a biologically active molecule that directs the compound to specific organs, tissues, or cellular receptors in the body. Once administered, usually through injection, ingestion, or inhalation, the radiopharmaceutical emits radiation that can either be detected by imaging technologies such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) for diagnostic purposes, or deliver targeted radiation to destroy diseased cells in therapeutic applications. Radiopharmaceuticals Market Report Metrics Details Coverage Global Study Period 2023-2034 Radiopharmaceuticals Market CAGR ~6% Radiopharmaceuticals Market Size by 2034 USD 24.1 Billion Key Radiopharmaceuticals Companies Lantheus, Cardinal Health, GE Healthcare, Curium Pharma, Pharmalogic Holdings Corp., Novartis, Cambridge Isotope Laboratories, Inc., Sotera Health LLC, Bracco Imaging SpA, Jubilant Pharma Limited, NECSA Ltd., IBA Radiopharma Solutions, Bayer AG, Norgine, NorthStar Medical Radioisotopes, LLC, Eckert & Ziegler, Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Mallinckrodt PLC, ROTOP Pharmaka GmbH, and others Radiopharmaceuticals Market Assessment Radiopharmaceuticals Market SegmentationRadiopharmaceuticals Market Segmentation By Product Type: Diagnostic Products [Single Photon Emission Computed Tomography (SPECT) {Technetium-99m, Iodine-125, Xenon-133, and Others} and Positron Emission Tomography (PET) {Flourine-18, Carbon-11, Gallium-68, and Others}], and Therapeutic Products [Alpha Emitters {Astatine-211, Actinium-225, Lead-212, and Others}, Beta Emitters {Lutetium-177, Iodine-131, Yttrium-90, and Others}, and Brachytherapy]Radiopharmaceuticals Market Segmentation By Application: Cardiology, Neurology, Oncology, and OthersRadiopharmaceuticals Market Segmentation By End-User: (Hospitals, Diagnostic Centers, and OthersRadiopharmaceuticals Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of WorldPorter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the radiopharmaceuticals market are set to emerge as the trendsetter explore @ Radiopharmaceuticals Market Analysis Table of Contents 1 Radiopharmaceuticals Market Report Introduction 2 Radiopharmaceuticals Market Executive Summary 3 Radiopharmaceuticals Market Key Factors Analysis 4 Impact Analysis 5 Regulatory Analysis 6 Radiopharmaceuticals Market Porter's Five Forces Analysis 7 Radiopharmaceuticals Market Assessment 8 Competitive Landscape 9 Startup Funding & Investment Trends 10 Radiopharmaceuticals Market Company and Product Profiles 11 KOL Views 12 Project Approach 13 About DelveInsight 14 Disclaimer & Contact Us Interested in knowing the radiopharmaceuticals market share by 2034? Click to get a snapshot of the Radiopharmaceuticals Market Size Related Reports Radioligand Therapies Market Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key RLT companies, including Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutic, Nuclidium, and others. PSMA-targeted Therapy Market PSMA-targeted Therapy Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key PSMA-targeted therapy companies, including Lantheus, Telix Pharmaceuticals, Novartis, and others. Prostate Cancer Market Prostate Cancer Market Insights, Epidemiology, and Market Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer companies, including Sanofi, AstraZeneca, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, and others. Positron Emission Tomography Market Positron Emission Tomography Market Insights, Competitive Landscape, and Market Forecast - 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key PET companies, including General Electric Company, Bruker Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., Canon Medical Systems Corporation, Positron Corporation, Shimadzu Corp., RefleXion, CMR Naviscan Corporation, Segami Corporation, Neusoft Medical Systems Co., Ltd., Mediso Ltd., Sofie Biosciences (PerkinElmer Inc.), United Imaging Healthcare Co., Ltd., MinFound Medical Systems Co., Ltd, MR Solutions, and others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur info@delveinsight.com +14699457679 Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg View original content:https://www.prnewswire.co.uk/news-releases/global-radiopharmaceuticals-market-set-for-significant-expansion-at-a-cagr-of-10-by-2034-with-increasing-adoption-of-targeted-radiotherapy--delveinsight-302774694.html © 2026 PR Newswire